ACE Insertion/Deletion Polymorphism (rs4646994) Is Associated With the Increased Risk of Multiple Myeloma
Szymon Zmorzyński(Medical University of Lublin), Agata Filip(Medical University of Lublin), Wojciech Styk(Medical University of Lublin), Magdalena Wojcierowska-Litwin(Medical University of Lublin), Marek Hus(Medical University of Lublin), Sylwia Popek-Marciniec(Medical University of Lublin), Grażyna Świderska-Kołacz(Jan Kochanowski University), Aneta Szudy‐Szczyrek(Medical University of Lublin), Małgorzata Luterek(Medical University of Lublin), Sylwia Chocholska(Medical University of Lublin), Iwona Korszeń-Pilecka(Medical University of Lublin), Michał Mielnik(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Joanna Januszewska
Cited by 36
Related Papers
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
|New England Journal of Medicine|2024|162
Therapy‐related peripheral neuropathy in multiple myeloma patients
|Hematological Oncology|2014|70